Valproate Sodium

Increased risk of methemoglobinemia when concurrently exposed to articaine.

Increased risk of developing methemoglobinemia when concurrently exposed to this anticonvulsant.

Increased risk of methemoglobinemia when concurrently exposed to this anticonvulsant oxidizing agent with local anesthetics.

Increased risk of methemoglobinemia when local anesthetics are used concomitantly with anticonvulsants.

Increased risk of methemoglobinemia when concurrently exposed with bupivacaine.

Anticonvulsant associated with increased methemoglobinemia risk when used with ropivacaine.

Valproate can inhibit lamotrigine metabolism and displace it from protein binding, potentially increasing lamotrigine concentrations significantly.

Increased risk of methemoglobinemia when used concurrently with lidocaine.

Anticonvulsant that may cause methemoglobinemia when used concomitantly with lidocaine patch 5%.

Anticonvulsant that increases risk of methemoglobinemia when used concurrently with lidocaine and capsaicin patch.

Anticonvulsant; increased risk of methemoglobinemia when concurrently exposed.

Increased risk of methemoglobinemia when used concurrently with lidocaine hydrochloride.

Anticonvulsant associated with increased methemoglobinemia risk when used concurrently.

Increased risk of methemoglobinemia when local anesthetic is concurrently exposed to anticonvulsants.

Concurrent exposure increases risk of methemoglobinemia in patients administered local anesthetics.

Increased risk of methemoglobinemia; anticonvulsants associated with methemoglobinemia when used with local anesthetics.

Increased risk of methemoglobinemia when used with lidocaine.

Increased risk of methemoglobinemia when lidocaine is concurrently exposed to anticonvulsants.

Increased risk of methemoglobinemia when local anesthetics are concurrently exposed to anticonvulsants.

Increased risk of methemoglobinemia when concurrently exposed to anticonvulsants.

Concurrent exposure increases risk of methemoglobinemia in patients administered mepivacaine.

Increased risk of methemoglobinemia when penicillin is concurrently administered with sodium valproate (an anticonvulsant).

Sodium valproate increases phenobarbital serum levels. Phenobarbital blood levels should be closely monitored and dosage adjustments made as clinically indicated.

Increased risk of methemoglobinemia when prilocaine is concurrently exposed to sodium valproate.

Increased risk of methemoglobinemia when used concurrently with prilocaine.

Increased risk of developing methemoglobinemia when concurrently exposed to sodium valproate.

Concomitant use of topiramate and valproate may result in hyperammonemia and encephalopathy.

Increased risk of methemoglobinemia when concurrently exposed.

Increased risk of methemoglobinemia when used concurrently with triethanolamine salicylate.

Increased risk of methemoglobinemia when used with Trubrexa Transdermal Patch.

Aspirin decreases protein binding of valproate and inhibits its metabolism, increasing valproate free fraction 4-fold and decreasing β-oxidation pathway. Monitoring of valproate concentrations is recommended.

Dosage adjustment of amitriptyline may be necessary if used concomitantly with valproate due to altered pharmacokinetics.

May increase risk of methemoglobinemia when concurrently exposed with bupivacaine.

Increased risk of methemoglobinemia when concurrently exposed.

Increased risk of developing methemoglobinemia when concurrently exposed.

Carbamazepine is an enzyme-inducing drug that can increase valproate clearance and may double it. Monitoring of valproate and carbamazepine concentrations and dosage adjustment are indicated.

Valproate can inhibit diazepam metabolism and displace it from protein binding, potentially increasing diazepam concentrations.

Estrogen-containing hormonal contraceptives may affect valproate pharmacokinetics. Monitoring of valproate concentrations is recommended.

Valproate can inhibit ethosuximide metabolism and displace it from protein binding, potentially increasing ethosuximide concentrations.

Felbamate is an enzyme inhibitor that can decrease valproate clearance. Monitoring of valproate and felbamate concentrations and dosage adjustment are indicated.

May increase or decrease plasma phenytoin concentrations; effects are unpredictable.

Anticonvulsant that increases risk of methemoglobinemia when used concomitantly with lidocaine and tetracaine.

Carbapenem antibiotics may affect valproate concentrations. Monitoring of valproate concentrations is recommended.

Increased risk of methemoglobinemia when concurrently exposed to anticonvulsants with bupivacaine.

Dosage adjustment of nortriptyline may be necessary if used concomitantly with valproate due to altered pharmacokinetics.

Sodium valproate decreases barbiturate metabolism. Barbiturate blood levels should be monitored and dosage adjustments made as needed.

Sodium valproate appears to decrease barbiturate metabolism. Barbiturate blood levels should be monitored and dosage adjustments made as indicated.

Phenytoin is an enzyme-inducing drug that can increase valproate clearance and may double it. Monitoring of valproate and phenytoin concentrations and dosage adjustment are indicated.

May increase or decrease phenytoin serum levels; monitoring of phenytoin levels recommended.

Primidone is an enzyme-inducing drug that can increase valproate clearance and may double it. Monitoring of valproate and primidone concentrations and dosage adjustment are indicated.

Dosage adjustment of propofol may be necessary if used concomitantly with valproate due to altered pharmacokinetics.

Rifampin is an enzyme-inducing drug that can increase valproate clearance. Monitoring of valproate and rifampin concentrations and dosage adjustment are indicated.

Ritonavir elevates glucuronosyltransferase levels and may increase the clearance of valproate.

Valproate increases rufinamide concentrations. Patients stabilized on rufinamide should begin valproate therapy at a low dose and titrate to clinically effective dose.

Dosage adjustment of warfarin may be necessary if used concomitantly with valproate due to altered pharmacokinetics.

Dosage adjustment of zidovudine may be necessary if used concomitantly with valproate due to altered pharmacokinetics.

Inhibits glucuronidation but does not affect haloperidol plasma concentrations; no clinically significant interaction.

Clonazepam The concomitant use of valproate and clonazepam may induce absence status in patients with a history of absence type seizures.

Lorazepam Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n = 9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.

Tolbutamide From in vitro experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate.